UK Fabry Disease Pricing Strategy Model

Agalsidase beta (Fabrazyme) has never gone through a formal NICE technology appraisal. NHS England commissions it as a highly specialised service via clinical policy, a route that predates today's Highly Specialised Technology (HST) pathway, at an estimated £150,000-250,000 per patient per year post-PAS across roughly 600 UK ERT patients. Migalastat (Galafold) followed a different route entirely: NICE's HST4 appraisal recommended it in 2016 as the first oral, mutation-specific rare disease therapy the body had approved, based on an indirect comparison against ERT rather than a head-to-head trial, at an estimated £80,000-120,000 per patient per year post-PAS for around 200 UK patients. Two drugs treating overlapping populations, priced through two different mechanisms, is the starting fact any pricing model for this indication has to reconcile before it can say anything useful about a third agent's entry point.

The switch economics between those two prices are where the real pricing story sits. Moving an amenable-mutation patient from agalsidase beta to migalastat saves the NHS an estimated £70,000-130,000 per patient per year, and NICE's own HST4 analysis already quantifies that saving. If uptake among eligible amenable-mutation patients reached 30%, a level the UK has not yet hit despite already running the highest reported migalastat uptake globally, total NHS savings could reach £20,000,000-40,000,000 per year against an ERT-only baseline. Pegunigalsidase alfa (Elfabrio) adds a third price point on top of this two-drug ladder: NICE's TA915 recommendation (2023) came with an agreed commercial arrangement, a PAS discount, justified by demonstrating subgroup-specific clinical superiority in the ADA-positive suboptimal-responder segment rather than the broad Fabry population, a pricing case any new entrant into that niche will be measured against.

Every AXLRx pricing model is built from primary NHS and NICE sources, including clinical commissioning policy documentation, published Final Evaluation and Technology Appraisal Determinations, and NHS England budget analysis, not secondary summaries or market-research estimates.

UK Fabry pricing sources: NHS England clinical commissioning policy (agalsidase beta), NICE HST4 Final Evaluation Determination (migalastat, 2016), NICE TA915 final guidance (pegunigalsidase alfa, 2023), NHS England lysosomal storage disorder commissioning budget analysis 2023, and Amicus UK market share data 2023.